氨溴索联合头孢哌酮舒巴坦治疗社区获得性肺炎临床疗效及C反应蛋白影响.docVIP

氨溴索联合头孢哌酮舒巴坦治疗社区获得性肺炎临床疗效及C反应蛋白影响 　　[摘要] 目的 对CAP应用氨溴索联合头孢哌酮舒巴坦治疗的效果进行探讨，并对C反应蛋白的影响进行分析。方法 方便选取该院2013年1月―2016年1月期间收治的CAP患者64例，随机分为观察组与对照组，各32例，对照组采用头孢哌酮舒巴坦治疗，观察组在对照组基础上给予氨溴索联合治疗，对两组患者治疗效果进行对比，并对治疗前后C反应蛋白水平进行对比分析。结果 经过治疗，观察组治疗总有效率为90.63%，对照组为68.75%，观察组明显高于对照组，差异有统计学意义（P0.05）；C反应蛋白方面，观察组（24.8±8.5）pg/mL治疗后明显低于治疗前（242.6±38.6）pg/mL，且治疗后明显低于对照组（76.6±10.6）pg/mL，差异有统计学意义（P0.05）。 结论 对CAP患者采用氨溴索联合头孢哌酮舒巴坦进行治疗，效果较好，能显著改善患者C反应蛋白水平，在临床中有推广应用的价值。 　　[?P键词] 重症社区获得性肺炎；氨溴索；头孢哌酮舒巴坦；C反应蛋白 　　[中图分类号] R969 [文献标识码] A [文章编号] 1674-0742（2017）03（b）-0131-03 　　[Abstract] Objective To discuss the clinical curative effect of ambroxol combined with cefoperazone sulbactam in treatment of community acquired pneumonia and effect on C reactive protein. Methods 64 case of CAP patients admitted and treated in our hospital from January 2013 to January 2016 were convenient selected and randomly divided into two groups with 32 cases in each， the control group were treated with cefoperazone sulbactam， while the observation group were treated with ambroxol on the basis of the control group， and the treatment effect was compared between the two groups， and The C reactive protein level before and after treatment was compared and analyzed. Results After treatment， the total effective rate in the observation group was obviously higher than that in the control group（90.63% vs 68.75%）， and the difference had statistical significance（P0.05）， the C reactive protein in the observation group after treatment was obviously lower than that before treatment and that in the control group after treatment[（24.8±8.5）pg/mL vs （242.6±38.6）pg/mL vs （76.6±10.6）pg/mL]， and the difference had statistical significance（P0.05）. Conclusion The treatment effect of ambroxol combined with cefoperazone sulbactam in treatment of community acquired pneumonia is good， which can obviously improve the C reactive protein level of patients， and it is worth clinical promotion and application in clinic. 　　[Key words] Community acquired pneumonia